UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 33-26787-D

Zynex, Inc.

NEVADA		90-0214497
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

9990 PARK MEADOWS DRIVE
LONE TREE, COLORADO		80124
(Address of principal executive offices)		(Zip Code)

(303) 703-4906

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer o		Accelerated filer o		Non-accelerated filer o		Smaller reporting company þ
				(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Shares Outstanding as of August 12, 2011
Common Stock, par value $0.001		30,794,479

 

 

ZYNEX, INC.
INDEX TO FORM 10-Q

		Page
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of June 30, 2011 (unaudited) and December 31, 2010			3
Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2011, and 2010			4
Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the six months ended June 30, 2011			5
Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2011 and 2010			6
Unaudited Notes to Condensed Consolidated Financial Statements			7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			15
Item 4. Controls and Procedures			20
PART II — OTHER INFORMATION
Item 1. Legal Proceedings			21
Item 5. Other Information			21
Item 6. Exhibits			22
Signatures			23
Exhibit 31.1
Exhibit 31.2
Exhibit 32.1
EX-101 INSTANCE DOCUMENT
EX-101 SCHEMA DOCUMENT
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101 LABELS LINKBASE DOCUMENT
EX-101 PRESENTATION LINKBASE DOCUMENT
EX-101 DEFINITION LINKBASE DOCUMENT

ITEM 1. FINANCIAL STATEMENTS

ZYNEX, INC.

		June 30,				December 31,
		2011				2010
		(UNAUDITED)
ASSETS
Current Assets:
Cash		$	783			$	602
Accounts receivable, net			9,513				7,309
Inventory			3,751				3,641
Prepaid expenses			136				145
Deferred tax asset			917				794
Other current assets			63				41
Total current assets			15,163				12,532
Property and equipment, net			3,239				2,906
Deposits			201				174
Deferred financing fees, net			91				89
Total assets		$	18,694			$	15,701
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Line of credit		$	3,204			$	1,270
Current portion of capital lease obligations			100				93
Accounts payable			1,458				1,313
Income taxes payable			911				1,103
Accrued payroll and payroll taxes			794				572
Deferred rent			259				221
Other accrued liabilities			1,367				980
Total current liabilities			8,093				5,552
Capital lease obligations, less current portion			274				327
Deferred rent			1,303				1,452
Deferred tax liability			230				188
Total liabilities			9,900				7,519
Stockholders’ Equity:
Preferred stock; $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding			—				—
Common stock, $.001 par value, 100,000,000 shares authorized, 30,775,034 (June 2011) and 30,604,167 (December 2010) shares issued and outstanding			31				31
Paid-in capital			4,940				4,702
Retained earnings			3,823				3,449
Total stockholders’ equity			8,794				8,182
Total liabilities and stockholders’ equity		$	18,694			$	15,701

See accompanying notes to unaudited condensed consolidated financial statements.

ZYNEX, INC.

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2011				2010				2011				2010
Net revenue:
Rental		$	2,447			$	2,335			$	4,895			$	4,606
Sales			5,948				3,407				10,133				6,011
			8,395				5,742				15,028				10,617
Cost of revenue:
Rental			392				258				726				533
Sales			1,335				964				2,445				1,685
			1,727				1,222				3,171				2,218
Gross profit			6,668				4,520				11,857				8,399
Selling, general and administrative expense			5,769				4,390				11,097				8,237
Income from operations			899				130				760				162
Other income (expense):
Interest income			1				3				1				4
Interest expense and loss on extinguishment of debt			(80	)			(53	)			(138	)			(132	)
Other income (expense)			2				2				2				(16	)
			(77	)			(48	)			(135	)			(144	)
Income before income tax			822				82				625				18
Income tax expense			(338	)			(52	)			(251	)			(55	)
Net income (loss)		$	484			$	30			$	374			$	(37	)
Net income (loss) per share:
Basic		$	0.02			$	*			$	0.01			$	**
Diluted		$	0.02			$	*			$	0.01			$	**
* Less than $0.01 per share
** Less than ($0.01) per share
Weighted average number of common shares outstanding:
Basic			30,756,717				30,513,285				30,694,216				30,505,347
Diluted			31,025,478				30,702,944				30,957,206				30,716,349

See accompanying notes to unaudited condensed consolidated financial statements.

ZYNEX, INC.

		Number				Common				Paid in				Retained
		of Shares				Stock				Capital				Earnings				Total
Balances as of January 1, 2011			30,604,167			$	31			$	4,702			$	3,449			$	8,182
Issuance of common stock
for option exercise			112,500				—				48				—				48
for consulting services			58,367				—				44				—				44
Employee stock-based compensation			—				—				146				—				146
Net income for the six months ended June 30, 2011			—				—				—				374				374
Balances as of June 30, 2011			30,775,034			$	31			$	4,940			$	3,823			$	8,794

See accompanying notes to unaudited condensed consolidated financial statements.

ZYNEX, INC.

		Six Months Ended
		June 30,
		2011				2010
Cash flows from operating activities:
Net income (loss)		$	374			$	(37	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation expense			389				401
Provision for losses on uncollectible accounts receivable			630				102
Amortization of financing fees			23				21
Issuance of common stock for services			44				48
Provision for obsolete inventory			—				(9	)
Deferred rent			(111	)			564
Net loss on disposal of equipment			—				18
Employee stock-based compensation expense			146				126
Deferred tax benefit			(81	)			(355	)
Changes in operating assets and liabilities:
Accounts receivable			(2,834	)			(1,257	)
Inventory			(93	)			(868	)
Prepaid expenses			9				107
Other current assets			(49	)			(19	)
Accounts payable			145				(25	)
Accrued liabilities			609				177
Income taxes payable			(192	)			(545	)
Net cash used in operating activities			(991	)			(1,551	)
Cash flows from investing activities:
Proceeds received in lease termination			—				108
Purchases of equipment and inventory used for rental			(739	)			(224	)
Net cash used in investing activities			(739	)			(116	)
Cash flows from financing activities:
Net borrowings from line of credit			1,934				1,087
Issuance of common stock			48				—
Deferred financing fees			(25	)			(90	)
Payments on capital lease obligations			(46	)			(146	)
Net cash provided by financing activities			1,911				851
Net increase (decrease) in cash			181				(816	)
Cash at beginning of period			602				863
Cash at end of period		$	783				47
Supplemental cash flow information:
Interest paid		$	102			$	51
Income taxes paid		$	525			$	955
Supplemental disclosure of non-cash investing and financing activities:
Equipment acquired through capital lease		$	—			$	334

See accompanying notes to unaudited condensed consolidated financial statements.

ZYNEX, INC.

(1) UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Zynex, Inc. and its wholly-owned subsidiaries, Zynex Medical, Inc., Zynex NeuroDiagnostics Inc. and Zynex Monitoring Solutions Inc. are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission and accounting principles generally accepted in the United States (U.S. GAAP). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the Securities and Exchange Commission in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010. Amounts as of December 31, 2010, are derived from those audited consolidated financial statements. These interim condensed consolidated financial statements should be read in conjunction therewith.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of June 30, 2011, and the results of operations and cash flows for the periods presented. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2011, are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

(2) SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

USE OF ESTIMATES

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the allowances for provider discounts and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation and income taxes.

REVENUE RECOGNITION, AND ALLOWANCES FOR PROVIDER DISCOUNTS AND COLLECTIBILITY

The Company recognizes revenue when each of the following four conditions are met: 1) a contract or sales arrangement exists; 2) products have been shipped and title has transferred, or rental services have been rendered; 3) the price of the products or services is fixed or determinable; and 4) collectability is reasonably assured. Accordingly, the Company recognizes revenue, both rental and sales, when products have been delivered to the patient and the patient’s insurance (if the patient has insurance) has been verified (if any). For medical products that are sold from inventories consigned at clinic locations, the Company recognizes revenue when it receives notice that the product has been prescribed and delivered to the patient and the patient’s insurance coverage has been verified or preauthorization has been obtained from the insurance company, when required. Revenue from the rental of products is normally on a month-to-month basis and is recognized ratably over the products’ rental period. Revenue from sales to distributors is recognized when the Company ships its products, which fulfills its order and transfers title. All revenue is recognized at amounts estimated to be received from customers or third-party providers using the Company’s established rates, net of estimated provider discounts.

ZYNEX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)
SIX MONTH PERIODS ENDED JUNE 30, 2011 AND 2010

(2) SIGNIFICANT ACCOUNTING POLICIES (continued)

A significant portion of the Company’s revenue is derived, and the related receivables are due, from insurance companies or other third-party payors. The nature of these receivables within this industry has typically resulted in long and varying collection cycles. The process of determining what products will be reimbursed by third-party providers and the amounts that they will reimburse is complex and depends on conditions and procedures that vary among providers and may change from time to time. The Company maintains an allowance for provider discounts and records additions to the allowance to account for the risk of nonpayment. Provider discounts result from reimbursements from insurance or other third party payors that are less than amounts claimed (billed), where the amount claimed by the Company exceeds the insurance or other payor’s usual, customary and reasonable reimbursement rate. The Company determines the amount of the allowance, and adjusts the allowance at the end of each reporting period, based on a number of factors, including historical rates of collection, the aging of the receivables, trends in the historical rates of collection and current relationships and experience with insurance companies or other third party payors. If the rate of collection of past-due receivables recorded for previous fiscal periods changes, or if there is a trend in the rates of collection on those receivables, the Company may be required to change the rate at which it provides for additions to the allowance. A change in the rates of the Company’s collections can result from a number of factors, including experience and training of billing personnel, changes in the reimbursement policies or practices of payors, or changes in industry rates of reimbursement. Accordingly, the provision for provider discounts recorded in the income statement as a reduction of revenue has fluctuated and may continue to fluctuate significantly from quarter to quarter.

Due to the nature of the industry and the reimbursement environment in which the Company operates, estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of third-party billing arrangements and the uncertainty of reimbursement amounts for certain products or services from payors may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party reimbursement, it is possible that management’s estimates could change in the near term, which could have an impact on results of operations and cash flows. Any differences between estimated settlements and final determinations are reflected as an increase or a reduction to revenue in the period when such final determinations are known.

The Company frequently receives refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in the Company’s industry. For example, on April 26, 2010, the Company received a refund request from Anthem Blue Cross Blue Shield (“Anthem”) covering the period from October 1, 2008 (the date of the last retrospective audit by Anthem) through March 12, 2010. These requests are sometimes related to a limited number of patients; at other times, they include a significant number of refund claims in a single request. The Company reviews and evaluates these requests and determines if any refund request is appropriate. The Company also reviews refund claims when it is rebilling or pursuing reimbursement from that insurance provider. The Company frequently has significant offsets against such refund requests, and sometimes amounts are due to the Company in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests, the Company is generally unable to determine if a refund request is valid and should be accrued. As of June 30, 2011, the Company believes it has adequate reserves relating to all known insurance disputes and refund requests. However, no assurances can be given with respect to such estimates of reimbursements and offsets or the ultimate outcome of the refund requests.

ZYNEX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)
SIX MONTH PERIODS ENDED JUNE 30, 2011 AND 2010

(2) SIGNIFICANT ACCOUNTING POLICIES (continued)

In addition to the allowance for provider discounts, the Company records an allowance for uncollectible accounts receivable. Uncollectible accounts receivable are primarily a result of the following: non-payment from patients who have been direct billed for co-payments or deductibles, lack of appropriate insurance coverage and disallowances of charges by third-party payors. If there is a change to a material insurance provider contract or policy, application by a provider, a decline in the economic condition of providers or a significant turnover of Company billing personnel resulting in diminished collection effectiveness, the estimate of the allowance for uncollectible accounts receivable may not be adequate and may result in an increase in the future.

At June 30, 2011 and December 31, 2010, the allowance for uncollectible accounts receivable is $1,590 and $1,262, respectively.

FAIR VALUE OF FINANCIAL INSTRUMENTS AND CREDIT RISK

The Company’s financial instruments at June 30, 2011 include cash, accounts receivable, accounts payable, capital lease obligations and the line of credit balance, for which current carrying amounts approximate fair value due to their short-term nature. At June 30, 2011 and December 31, 2010, the Company had no financial assets or liabilities subject to recurring fair value measurement.

RECLASSIFICATIONS

Certain reclassifications to the 2010 cash flow statement and balance sheet have been made to conform to the 2011 presentation, none of which had any effect on cash flows from operating, investing and financing activities or total assets, total liabilities or stockholders’ equity.

INVENTORY

Inventories are valued at the lower of cost (average) or market. Finished goods include products held at the Company’s headquarters and at different locations by health care providers or other third parties for rental or sale to patients.

The Company monitors inventory for turnover and obsolescence, and records losses for excess and obsolete inventory as appropriate. At June 30, 2011, the Company had a reserve for obsolete and damaged inventory of approximately $532 and a reserve of approximately $549 at December 31, 2010. The Company had $2,473 of open purchase commitments at June 30, 2011.

PROPERTY AND EQUIPMENT

Property and equipment as of June 30, 2011 and December 31, 2010, are as follows:

		June 30,				December 31,
		2011				2010				Useful lives
Office furniture and equipment		$	1,295			$	1,194			3-7 years
Rental equipment			2,541				2,108			5 years
Vehicles			—				60			5 years
Leasehold improvements			407				370			2-6 years
Assembly equipment			11				11			7 years
			4,254				3,743
Less accumulated depreciation			(1,015	)			(837	)
		$	3,239			$	2,906

ZYNEX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)
SIX MONTH PERIODS ENDED JUNE 30, 2011 AND 2010

(2) SIGNIFICANT ACCOUNTING POLICIES (continued)

RECENT ACCOUNTING PRONOUNCEMENTS

In July 2011, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2011-07, “Health Care Entities (Topic 954): Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities”, which requires that certain health care entities change the presentation of their statement of operations by reclassifying the provision for bad debts associated with patient service revenue from an operating expense to a deduction from patient service revenue (net of contractual allowances and discounts). In addition, the amendments also require enhanced disclosure about policies for recognizing revenue and assessing bad debts and disclosures of qualitative and quantitative information about changes in the allowance for doubtful accounts. This ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2011, with early adoption permitted. Management currently expects that this ASU will not have a material impact on the Company’s consolidated financial statements.

(3) EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding and the number of dilutive potential common share equivalents during the period, calculated using the treasury-stock method.

The calculation of basic and diluted earnings per share for the three and six months ended June 30, 2011 and 2010 is as follows:

		Three months ended								Six months ended
		June 30,								June 30,
		2011				2010				2011				2010
Basic:
Net income (loss)		$	484			$	30			$	374			$	(37	)
Weighted average shares outstanding — basic			30,756,717				30,513,285				30,694,216				30,505,347
Net income per share — basic		$	0.02			$	*			$	0.01			$	**
Diluted:
Net income (loss)		$	484			$	30			$	374			$	(37	)
Weighted average shares outstanding — basic			30,756,717				30,513,285				30,694,216				30,505,347
Dilutive securities			268,761				189,659				262,990				211,002
Weighted average shares outstanding — diluted			31,025,478				30,702,944				30,957,206				30,716,349
Net income per share — diluted		$	0.02			$	*			$	0.01			$	**

The effects of potential common stock equivalents for the six months ended June 30, 2010 (1,681,898 shares) have not been included in the computation of diluted loss per share as the impact of the potential common shares would be anti-dilutive.

ZYNEX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)

SIX MONTH PERIODS ENDED JUNE 30, 2011 AND 2010

(4) STOCK-BASED COMPENSATION PLANS

The Company has a 2005 Stock Option Plan (the “Option Plan”) and has reserved 3,000,000 shares of common stock for issuance under the Option Plan. Vesting provisions are determined by the Board of Directors. All stock options under the Option Plan expire no later than ten years from the date of grant.

For the three months ended June 30, 2011 and 2010, the Company recorded compensation expense related to stock options of $68 and $65, respectively. For the six months ended June 30, 2011 and 2010, the Company recorded compensation expense related to stock options of $146 and $126, respectively. The stock-based compensation expense was included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations.

For the six months ended June 30, 2011, the Company granted options to purchase up to 173,500 shares of common stock to employees at exercise prices that ranged from $0.62 to $1.06 per share. During the six months ended June 30, 2010, the Company granted options to purchase up to 178,500 shares of common stock at exercise prices that ranged from $0.63 to $1.06 per share.

The Company used the Black-Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions during the six months ended June 30, 2011 and 2010:

		2011		2010
Expected term		6.25 years		6.25 years
Volatility		105.9% - 107.6%		110.8% - 113.6%
Risk-free interest rate		2.74% - 2.90%		2.62% - 3.36%
Dividend yield		0%		0%

The expected term of stock options represents the period of time that the stock options granted are expected to be outstanding based on historical exercise trends. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury bill rate for the expected term of the related stock options. The dividend yield represents the Company’s anticipated cash dividend over the expected term of the stock options. Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the six months ended June 30, 2011 and 2010 was 35%.

ZYNEX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)
SIX MONTH PERIODS ENDED JUNE 30, 2011 AND 2010

(4) STOCK-BASED COMPENSATION PLANS (continued)

A summary of stock option activity under the Option Plan for the six months ended June 30, 2011, is presented below:

										Weighted
						Weighted				Average
		Shares				Average				Remaining		Aggregate
		Under				Exercise				Contractual		Intrinsic
		Option				Price				Life		Value
Outstanding at January 1, 2011			1,845,250			$	0.96
Granted			173,500			$	0.66
Exercised			(112,500	)		$	0.43
Forfeited			(205,500	)		$	0.78
Outstanding at June 30, 2011			1,700,750			$	0.99			7.1 Years		$	212
Exercisable at June 30, 2011			699,125			$	1.15			3.7 Years		$	75

A summary of status of the Company’s non-vested share awards as of and for the six months ended June 30, 2011, is presented below:

		Nonvested Shares				Weighted Average
		Shares Under Option				Grant Date Fair Value
Non-vested at January 1, 2011			1,195,750			$	0.79
Granted			173,500			$	0.58
Vested			(189,625	)		$	0.89
Forfeited			(178,000	)		$	0.62
Non-vested at June 30, 2011			1,001,625			$	0.76

As of June 30, 2011, the Company had approximately $499 of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of approximately four years.

(5) INCOME TAXES

The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year. The Company paid income taxes of $525 during the first six months of 2011, which was included in income taxes payable at December 31, 2010. For the six months ended June 30, 2011, permanent differences are added back to net income resulting in a higher taxable income for purposes of calculating income tax expense or benefit. On July 13, 2011, the Company received a letter from the Internal Revenue Service (“IRS”) denying the Company’s request for abatement of penalties and interest incurred and previously recorded in 2010. The Company is in the process of appealing the denial and intends to mitigate partial or full payment of these penalties and interest.

ZYNEX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)
SIX MONTH PERIODS ENDED JUNE 30, 2011 AND 2010

(6) LINE OF CREDIT

In February 2011, the Company entered into an amendment to its revolving credit and security agreement with CapitalSource Bank (the “Credit Agreement”) to add Zynex Monitoring Solutions Inc. and Zynex NeuroDiagnostic Inc. to the Credit Agreement and to amend certain financial covenants. The Company has an asset-based revolving line of credit (“RLOC”) under the Credit Agreement that allows borrowing, repayment and re-borrowing, subject to the lesser of the facility cap of $3,500 or 85% of the borrowing base less certain reserved amounts. The borrowing base is generally the net collectible dollar value of the Company’s eligible accounts receivable, as defined. The Credit Agreement bears interest at a floating rate based on the one-month London interbank offered rate (LIBOR), divided by the sum of one minus a measure of the aggregate maximum reserve requirement for “Eurocurrency Liabilities” for the previous month, as defined, plus 4.0%. Interest is payable monthly. As of June 30, 2011, the effective interest rate under the Credit Agreement was 12% (7% interest rate and 5% fees). As of June 30, 2011, $3,204 was outstanding on the Credit Agreement (the remaining amount available for borrowing was $296).

As of June 30, 2011, the Company was current in its interest payments, but was not in compliance with its cash velocity financial covenant, and therefore the amount outstanding on the Credit Agreement is callable at any time by the lender. The Company is working with its lender to amend certain terms on the Credit Agreement, primarily to increase the amount of the facility cap and decrease the interest costs, and has requested a waiver for the June 30, 2011 financial covenant violation. Although the Company expects to enter into an amendment with the lender and obtain a waiver, no assurances can be given. If a waiver is not obtained, the lender can demand immediate payment of amounts outstanding under the Credit Agreement, and restrict or prevent the Company from borrowing while in default, which could have a material adverse impact on the Company’s cash flow and liquidity.

(7) CONCENTRATIONS

The Company had a receivable from one private health insurance carrier at June 30, 2011 that made up approximately 26% of the net accounts receivable balance. The same private health insurance carrier made up approximately 27% and of net accounts receivable at December 31, 2010.

(8) LITIGATION

A lawsuit was filed against the Company, its President and Chief Executive Officer and its former Chief Financial Officer on April 6, 2009, in the United States District Court for the District of Colorado (Marjorie and David Mishkin v. Zynex, Inc. et al.). On April 9 and 10, 2009, two other lawsuits were filed in the same court against the same defendants. These lawsuits alleged substantially the same matters and have been consolidated. On April 19, 2010, the plaintiffs filed a Consolidated Class Action Complaint (Civil Action No. 09-cv-00780-REB-KLM). The consolidated lawsuit refers to the April 1, 2009 announcement by the Company that it would restate its unaudited interim financial statements for the first three quarters of 2008. The lawsuit purports to be a class action on behalf of purchasers of the Company’s securities between May 21, 2008 and March 31, 2009. The lawsuit alleges, among other things, that

ZYNEX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)
SIX MONTH PERIODS ENDED JUNE 30, 2011 AND 2010

(8) LITIGATION (continued)

the defendants violated Section 10 and Rule 10b-5 of the Securities Exchange Act of 1934 by making intentionally or recklessly untrue statements of material fact and/or failing to disclose material facts regarding the financial results and operating conditions for the first three quarters of 2008. The plaintiffs asked for a determination of class action status, unspecified damages and costs of the legal action.

On May 17, 2010, the Company filed a Motion to Dismiss. The plaintiffs filed an Opposition to Defendant’s Motion to Dismiss, and on July 5, 2010, the Company filed a Reply in Support of Defendant’s Motion to Dismiss. On March 30, 2011, the United States District Court of Colorado entered an Order denying the Company’s motion to dismiss. The Company continues to believe that the allegations are without merit and will vigorously defend itself in the lawsuit. The Company has notified its directors and officers liability insurer of the claim. At this time, the Company is not able to determine the likely outcome of the legal matters described above, nor can it estimate its potential financial exposure. Litigation is subject to inherent uncertainties, and if an unfavorable resolution of any of these matters occurs, the Company’s business, results of operations, and financial condition could be adversely affected.

An additional lawsuit was filed on July 28, 2011 against the Company, its President and Chief Executive Officer, its former Chief Financial Officer and certain of its directors in the United States District Court for the District of Colorado (Stephen Hatch, derivatively, on behalf of Zynex Inc. v. Thomas Sandgaard et. al., 11-CV-01964). The lawsuit purports to be a shareholder derivative claim and alleges a breach of fiduciary duty by the Company’s officers and directors in connection with restatement of the Company’s unaudited interim financial statements for the first three quarters of 2008. The Company believes the claims are without merit and intends to defend this lawsuit vigorously.

The Company is not a party to any other material pending or threatened legal proceedings.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Special Cautionary Notice Regarding Forward-Looking Statements

This quarterly report contains statements that are forward-looking, such as statements relating to plans for future expansion and other business development activities, as well as the impact of reimbursement trends, other capital spending and financing sources. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. These risks include the need for additional capital in order to grow our business, our ability to engage additional sales representatives, the need to obtain Federal Drug and Administration (“FDA”) clearance and Certificate European (“CE”) marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers for reimbursement, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on third-party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our Annual Report on Form 10-K for the year ended December 31, 2010.

These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes thereto, included in the Company’s 2010 Annual Report on Form 10-K, which has previously been filed with the Securities and Exchange Commission.

The Company currently has three wholly-owned subsidiaries; Zynex Medical, Inc., Zynex NeuroDiagnistics Inc. and Zynex Monitoring Solutions Inc. As of June 30, 2011, Zynex NeuroDiagnostics Inc., formed in April 2010 to develop and market neurological diagnosis products for hospitals and clinics, and Zynex Monitoring Solutions Inc., formed in April 2010 to develop and market cardiovascular monitoring for hospitals and clinics, did not have any significant revenues.

RESULTS OF OPERATIONS (Amounts in thousands):

Revenue

Our products may be rented on a monthly basis or purchased. Renters and purchasers are primarily patients and healthcare providers on behalf of patients. Our products may also be purchased by dealers. If a patient is covered by health insurance, the third party payor typically determines whether the patient will rent or purchase a unit depending on the anticipated time period for its use. If contractually arranged, a rental continues until an amount equal to the purchase price is paid when we transfer ownership of the product to the patient and cease rental charges. We also sell consumable supplies, consisting primarily of surface electrodes and batteries that are used in conjunction with our electrotherapy products.

Revenue is reported net, after adjustments for uncollectable and estimated insurance company reimbursement deductions. The deductions are known throughout the health care industry as “contractual adjustments” whereby the healthcare insurers unilaterally reduce the amount they reimburse for our products as compared to the rental rates and sales prices charged by us. The deductions from gross revenue also take into account the estimated denials of claims for our products placed with patients and other factors which may affect collectability. See Note 2 to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report for a more complete explanation of revenue recognition.

Total Net Revenue (Rental and Sale).

		Three months ended								Six months ended
		June 30,				June 30,				June 30,				June 30,
		2011				2010				2011				2010
Total net revenue by type (in thousands):
Net Rental Revenue		$	2,447			$	2,335			$	4,895			$	4,606
Sales of electrotherapy and other privately-labeled distributed products			2,861				1,155				4,370				1,771
Sales of recurring consumable supplies			3,087				2,252				5,763				4,240
Total Net Sales Revenue			5,948				3,407				10,133				6,011
Total Net Revenue		$	8,395			$	5,742			$	15,028			$	10,617

Total net revenue increased $2,653 or 46% to $8,395 for the three months ended June 30, 2011, from $5,742 for the three months ended June 30, 2010. Total net revenue increased $4,411 or 42% to $15,028 for the six months ended June 30, 2011, from $10,617 for the six months ended June 30, 2010.

The increase in total net revenue for the three and six months ended June 30, 2011, compared to the three and six months ended June 30, 2010, was due primarily to a 42% and 34% increase in prescriptions (orders) for our electrotherapy products, for the respective three and six month periods in 2011 as compared to the same periods in 2010, and a 37% and 36% increase in our recurring consumable supplies (surface electrodes and batteries) for the three and six months ended June 30, 2011, respectively, as compared to the same periods in 2010. The increased orders are directly related to our continued addition of industry-experienced sales representatives, which benefit us by serving markets that we had not yet penetrated and provide greater awareness of our products to end users and physicians. As of June 30, 2011, we had 176 sales representatives versus 104 as of June 30, 2010 and currently have 193. The increased consumable supplies are directly related to the increased number of active products currently in the market.

The incremental addition of industry-experienced sales representatives allowed us to increase our market presence and increase orders during the first six months of 2011. Orders for our products lead to (1) rental income, which we anticipate receiving on a recurring basis over the time patients use our products, (2) direct sales of our products, and (3) corresponding recurring sales of electrodes and other supplies for our products, all of which are subject to our ability to collect due to contractual adjustments by insurers. Our products are subject to reimbursement policies of third-party payors, which we may not be able to determine with any certainty. These third-party payor policies typically dictate whether our products will be purchased or rented. Therefore, our revenue mix of net rental and net sales revenue may fluctuate from time to time and may not be an indicator of the overall demand for our products. Shifts in our revenue mix may also have a material impact on our overall gross margin, as product sales result in a lower gross profit because their cost of sales is higher than that from rentals (cost of sales associated with rentals is primarily depreciation).

Net Rental Revenue

Net Rental Revenue increased $112 or 5% to $2,447 for the three months ended June 30, 2011, from $2,335 for the three months ended June 30, 2010. Net Rental Revenue increased $289 or 6% to $4,895 for the six months ended June 30, 2011, from $4,606 for the six months ended June 30, 2010.

Net Rental Revenue for the three and six months ended June 30, 2011 represented 29% and 33%, respectively, of total net revenue compared to 41% and 43%, respectively, for the three and six months ended June 30, 2010. The increase in net rental revenue for the three and six months ended June 30, 2011 is primarily due to the overall increase in orders in 2011, subject to the varying reimbursement policies of third-party payors for our products that determine if a unit will be purchased or rented (on a patient by patient basis). We are unable to determine if the reimbursement policy trend towards purchasing or renting our products will continue or change in the future, as it is based on many market and third party payor factors. However, we believe that based on the current demand for our products, a change in reimbursement policy will not have a significant impact on our total revenue, as we believe it will only shift our revenue mix.

Net Sales Revenue

Net Sales Revenue increased $2,541 or 75% to $5,948 for the three months ended June 30, 2011, from $3,407 for the three months ended June 30, 2010. Net Sales Revenue increased $4,122 or 69% to $10,133 for the six months ended June 30, 2011, from $6,011 for the six months ended June 30, 2010.

Net Sales Revenue for the three and six months ended June 30, 2011 represented 71% and 67%, respectively, of total net revenue compared to 59% and 57%, respectively, for the three and six months ended June 30, 2010. Net Sales Revenue is comprised of two primary components: sales of electrotherapy devices and private labeled distributed products, representing 34% and 29%, respectively, of total net revenue for the three and six months ended June 30, 2011, and sales of recurring device consumables (batteries and electrodes), representing 37% and 38%, respectively, of total net revenue for the three and six months ended June 30, 2011. This compares to the sale of electrotherapy devices and private labeled distributed products representing 20% and 17%, respectively, of total net revenue for the three and six months ended June 30, 2010 and sale of device consumables representing 39% and 40%, respectively, of total net revenue for the three and six months ended June 30, 2010. The increase in Net Sales Revenue for the three and six months ended June 30, 2011 was primarily due to the respective 42% and 34% increase in orders over the same periods in 2010, the change in third-party payor reimbursement trend, in favor of purchasing products rather than renting them, and the increased number of units in the market (previously sold or actively being rented). These additional units in the market resulted in a 37% and 36%, respective increase of our recurring consumable supplies over the comparable three and six month periods for 2010.

Gross Profit

Total gross profit for the three and six months ended June 30, 2011 was $6,668 (or 79% of total net revenue) and $11,857 (or 79% of total net revenue), respectively, compared to $4,520 (or 79% of total net revenue) and $8,399 (or 79% of total net revenue), respectively, in the three and six months ended June 30, 2010.

Total gross profit percentage for the three and six months ended June 30, 2011 remained consistent with the total gross profit percentage for the three and six months ended June 30, 2010. Our total gross profit percentage was impacted by two primary items for the three and six months ended June 30, 2011, the increase in total net revenue and revenue mix. During the three and six month periods ended June 30, 2011 we experienced a 46% and 42% increase in total net revenue over the comparable periods in 2010. The total net revenue increase for the periods positively impacted our gross profit percentage, as we had incremental net revenue that exceeded fixed costs in manufacturing. The positive effect on gross profit percentage from our increase in total net revenue was offset by the change in revenue mix from more products being sold than rented. Product sales incur higher costs than those from rentals, as the major cost associated with rentals is depreciation. Net product rentals for the three and six months ended June 30, 2011 represented 29% and 33%, respectively, of total net revenue as compared to 41% and 43% for the respective periods in 2010.

Selling, General and Administrative (“SG&A”)

Total selling, general and administrative expenses increased $1,379 or 31% to $5,769 for the three months ended June 30, 2011 from $4,390 for the three months ended June 30, 2010. Total selling, general and administrative expenses increased $2,860 or 35% to $11,097 for the six months ended June 30, 2011 from $8,237 for the six months ended June 30, 2010.

A summary of selling, general and administrative expenses by department for the three and six months ended June 30, 2011 and 2010 is provided below:

		Three months ended																Six months ended
		June 30,				% of Net				June 30,				% of Net				June 30,				% of Net				June 30,				% of Net
SG&A expense by department		2011				Revenue				2010				Revenue				2011				Revenue				2010				Revenue
Sales & Marketing		$	2,214				26	%		$	1,546				27	%		$	3,966				26	%		$	2,954				28	%
Reimbursement & Billing			2,197				26	%			1,676				29	%			4,443				30	%			3,110				29	%
General & Administrative			966				12	%			767				13	%			1,903				13	%			1,389				13	%
Engineering & Operations (including Research and Development)			392				5	%			401				7	%			785				5	%			784				7	%
Total SG&A expenses		$	5,769							$	4,390							$	11,097							$	8,237

Our sales and marketing expenses increased by $668 and $1,012, for the three and six months ended June 30, 2011 over the same periods in 2010, respectively, due to incremental commissions incurred in the current periods (total orders increased 42% and 34%, respectively, for the three and six month periods in 2011 over the same periods in 2010). We incurred additional expenses in our reimbursement and billing department of $521 and $1,333, respectively, for the three and six month periods ended June 30, 2011 over the same periods in 2010, primarily because of additional personnel added to support the increase in total net revenue for 2011 and to further increase our cash collections from third party payors. Our reimbursement and billing department relies on personnel, processes and systems to negotiate and collect from third-party payors. Therefore, we continue to evaluate and invest in this department, as it is our primary function for cash collections. Improvements in our reimbursement and billing function may lead to higher revenues, as better negotiations and collection efforts with third-party payors could result in an increase to our aggregate accounts receivable collection percentage. We also incurred additional expense in our reimbursement and billing department for severance related to the retirement of the Company’s Vice President of Reimbursement and Billing in February 2011, reflected in the six months ended June 30, 2011 expenses (for additional information refer to Note 13 of the financial statements in our 2010 Annual Report on Form 10-K). Our general and administrative expenses increased by $199 and $514, respectively, for the three and six months ended June 30, 2011 over the same periods in 2010, which was primarily the result of administrative infrastructure, including the addition of regulatory personnel, required to support the increase in 2011 total net revenue. Engineering and operations decreased by $9 for the three months ended June 30, 2011 over the same period in 2010 and increased by $1 for the six months ended June 30, 2011 over the same period in 2010.

Other Income (Expense)

Other income (expense) is comprised of interest income, interest expense and other expense.

Interest income for the three and six months ended June 30, 2011 was less than $1 in each period, compared to $3 and $4 for the same periods in 2010.

Interest expense for the three and six months ended June 30, 2011 was $80 and $138, respectively, compared to $53 and $132 for the same periods in 2010. We increased the use of our revolving line of credit during the first six months of 2011 based on working capital needs, which resulted in a revolving line of credit balance of $3,204 as of June 30, 2011, versus a balance of $1,088 as of June 30, 2010. During the first quarter of 2010, we incurred an early termination fee of $70 related to our prior line of credit, which resulted in higher interest expense for the period.

Other income (expense) for the three and six months ended June 30, 2011 was $2 for both periods as compared to $2 and ($16) for the same periods in 2010. The other expense of ($16) reported in the six months ended June 30, 2010 was primarily the result of a loss on a net lease termination.

Income Tax Expense

Income tax expense for the three and six months ended June 30, 2011 was $338 and $251, respectively, compared to $52 and $55 for the same periods in 2010. The increase in income tax expense for the 2011 periods is primarily due to the $822 and $625 income before tax recorded for the three and six months ended June 30, 2011 versus $82 and $18 for the same periods in 2010. We also have permanent differences (expenses which are not deductible for income tax reporting) which create taxable income greater than the income before taxes in our statement of operations. The taxes on this taxable income cause the income tax expense to be at a higher effective tax rate than the statutory tax rate. On July 13, 2011, we received a letter from the Internal Revenue Service (“IRS”) denying our request to abate penalties and interest incurred and previously recorded in 2010. We are in the process of appealing the denial, and we intend to mitigate partial or full payment of these penalties and interest.

LIQUIDITY AND CAPITAL RESOURCES:

Line of Credit

In February 2011 we entered into an amendment to our revolving credit and security agreement with CapitalSource Bank (“Credit Agreement”). We have an asset-based revolving line of credit (“RLOC”) under the Credit Agreement that allows us to borrow, repay and re-borrow, subject to the lesser of the facility cap of $3,500 or 85% of the borrowing base less certain reserved amounts. The borrowing base is generally the net collectible dollar value of the Company’s eligible accounts receivable, as defined. The Credit Agreement bears interest at a floating rate based on the one-month London interbank offered rate (LIBOR), divided by the sum of one minus a measure of the aggregate maximum reserve requirement for “Eurocurrency Liabilities” for the previous month, as defined, plus 4.0%. Interest is payable monthly. As of June 30, 2011, the effective interest rate under the Credit Agreement was 12% (7% interest rate and 5% fees). As of June 30, 2011, $3,204 was outstanding under the Credit Agreement.

As of June 30, 2011, the Company was current in its interest payments, but was not in compliance with its cash velocity financial covenant, and therefore the amount outstanding on the Credit Agreement is callable at any time by the lender. We are working with our lender to amend certain terms on our Credit Agreement, primarily to increase the amount of the facility cap and decrease the interest costs, and we have requested a waiver for our June 30, 2011 financial covenant violation. Although we expect to enter into an amendment with our lender and obtain a waiver, we cannot provide any assurance. If a waiver is not obtained, the lender can demand immediate payment of amounts outstanding under the Credit Agreement, and restrict or prevent us from borrowing while we are in default, which could have a material adverse impact on our cash flow and liquidity.

Limited Liquidity

Cash at June 30, 2011 was $783, compared to cash at December 31, 2010 of $602.

Cash used in operating activities was $991 for the six months ended June 30, 2011 compared to $1,551 of cash used in operating activities for the six months ended June 30, 2010. The primary uses of cash from operations for the six months ended June 30, 2011 was the result of decreases in collections on accounts receivable and a partial payment of 2010 income taxes, offset by net income and non-cash items. The primary uses of cash from operations for the six months ended June 30, 2010, was the result of decreases in collections on accounts receivable, increases to inventory and a partial payment of 2009 income taxes, offset by non-cash items.

Cash used in investing activities for the six months ended June 30, 2011 was $739 compared to cash used in investing activities of $116 for the six months ended June 30, 2010. Cash used in investing activities for the six months ended June 30, 2011 primarily represents the purchase and in-house production of rental products as well as purchases of capital equipment. Cash used in investing activities for the six months ended June 30, 2010 primarily represents the purchase and in-house production of rental products and purchases of capital equipment, offset by proceeds received in a lease termination.

Cash provided by financing activities was $1,911 for the six months ended June 30, 2011 compared with cash provided by financing activities of $851 for the six months ended June 30, 2010. The primary financing sources of cash for the six months ended June 30, 2011 were net borrowings under the Credit Agreement and cash received from the exercise of stock options, partially offset by payments on capital lease obligations and deferred financing fees. The primary financing sources of cash for the six months ended June 30, 2010 were net borrowings under the Credit Agreement, partially offset by payments on capital lease obligations and deferred financing fees.

We have limited liquidity. Our limited liquidity is primarily a result of (a) the high level of outstanding accounts receivable because of deferred payment practices of third-party health payors, (b) the required high levels of inventory kept with sales representatives that are standard in the electrotherapy industry, (c) the payment of commissions to salespersons based on sales or rental orders prior to payments for the corresponding product by insurers and whether or not there is a denial of any payment by an insurer (d) the need for expenditures to continue to enhance the Company’s internal billing processes, (e) the delayed cost recovery inherent in rental transactions and (f) increased commitments resulting from the premises lease signed in November 2009. As our business and sales grow, some of these liquidity strains will increase. Limited liquidity may restrict our ability to carry out our current business plans and curtail our revenue growth.

Our long-term business plan continues to contemplate growth in revenues and thus to require, among other things, funds for the purchases of equipment, primarily for rental inventory, the payment of commissions to an increasing number of sales representatives, and the increase in office lease payments (for our new, larger building) to support the higher level of operations.

We believe that our cash flows from operating activities and borrowing availability under the RLOC will fund our cash requirements through June 30, 2012.

The availability of the RLOC depends upon our ongoing compliance with covenants, representations and warranties in the agreement for the RLOC and borrowing base limitations. Although the maximum amount of the line of credit is $3,500, the amount available for borrowing under the line of credit is subject to a ceiling based upon eligible receivables and other limitations and may be less than the maximum amount. As of June 30, 2011, $3,204 was outstanding on the Credit Agreement (the remaining amount available for borrowing was $296). As of August 5, 2011, the amount outstanding on the Credit Agreement was $2,611.

There is no assurance that our operations and available borrowings will provide enough cash for operating requirements or for increases in our inventory of products, as needed, for growth. We may need to seek external financing through the sale of debt or equity securities, and we are not certain whether any such financing would be available to us on acceptable terms or at all. Any additional debt would require the approval of CapitalSource Bank.

Our dependence on operating cash flow means that risks involved in our business can significantly affect our liquidity. Contingencies such as unanticipated shortfalls in revenues or increases in expenses could affect our projected revenue, cash flows from operations and liquidity which may force us to curtail our operating plan or impede our growth.

We frequently receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in our industry. For example, as previously disclosed, on April 26, 2010, we received a refund request from Anthem Blue Cross Blue Shield (“Anthem”) covering the period from October 1, 2008 (the date of the last retrospective audit by Anthem) through March 12, 2010. These requests are sometimes related to a few patients and other times include a significant number of refund claims in a single request. We review and evaluate these requests and determine if any refund is appropriate. We also review claims where we are rebilling or pursuing additional reimbursement from that insurance provider. We frequently have significant offsets against such refund requests which may result in amounts that are due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests we are generally unable to determine if a refund request is valid and should be accrued as a liability. As of June 30, 2011, we believe we have an adequate allowance for provider discounts relating to known insurance disputes and refund requests. However, no assurances can be given with respect to such estimates of reimbursements and offsets or the ultimate outcome of the refund requests.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES:

There are several accounting policies that involve management’s judgments and estimates and are critical to understanding our historical and future performance, as these policies and estimates affect the reported amounts of revenue and other significant areas in our reported financial statements.

Please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operation” located within our Annual Report on Form 10-K filed on March 28, 2011 for the year ended December 31, 2010, and Note 2 to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report for further discussion of our “Critical Accounting Policies.”

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the Company’s disclosure controls and procedures as of June 30, 2011. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2011.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the quarter ended June 30, 2011 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

A lawsuit was filed against the Company, its President and Chief Executive Officer and its former Chief Financial Officer on April 6, 2009, in the United States District Court for the District of Colorado (Marjorie and David Mishkin v. Zynex, Inc. et al.). On April 9 and 10, 2009, two other lawsuits were filed in the same court against the same defendants. These lawsuits alleged substantially the same matters and have been consolidated. On April 19, 2010, plaintiffs filed a Consolidated Class Action Complaint (Civil Action No. 09-cv-00780-REB-KLM). The consolidated lawsuit refers to the April 1, 2009 announcement by the Company that it would restate its unaudited interim financial statements for the first three quarters of 2008. The lawsuit purports to be a class action on behalf of purchasers of the Company’s securities between May 21, 2008 and March 31, 2009. The lawsuit alleges, among other things, that the defendants violated Section 10 and Rule 10b-5 of the Securities Exchange Act of 1934 by making intentionally or recklessly untrue statements of material fact and/or failing to disclose material facts regarding the financial results and operating conditions for the first three quarters of 2008 and other misleading statements. The plaintiffs ask for a determination of class action status, unspecified damages and costs of the legal action.

On May 17, 2010, the Company filed a Motion to Dismiss. The plaintiffs filed an Opposition to Defendant’s Motion to Dismiss, and on July 5, 2010, the Company filed a Reply in Support of Defendant’s Motion to Dismiss. On March 30, 2011, the United States District Court of Colorado entered an Order denying the Company’s motion to dismiss. The Company continues to believe that the allegations are without merit and will vigorously defend itself in the lawsuit. The Company has notified its directors and officers liability insurer of the claim. At this time, the Company is not able to determine the likely outcome of the legal matters described above, nor can it estimate its potential financial exposure. Litigation is subject to inherent uncertainties, and if an unfavorable resolution of any of these matters occurs, the Company’s business, results of operations, and financial condition could be adversely affected.

An additional lawsuit was filed on July 28, 2011 against the Company, its President and Chief Executive Officer, its former Chief Financial Officer and certain of its directors in the United States District Court for the District of Colorado (Stephen Hatch, derivatively, on behalf of Zynex Inc. v. Thomas Sandgaard et. al., 11-CV-01964). The lawsuit purports to be a shareholder derivative claim and alleges a breach of fiduciary duty by the Company’s officers and directors in connection with restatement of the Company’s unaudited interim financial statements for the first three quarters of 2008. The Company believes the claims are without merit and intends to defend this lawsuit vigorously.

The Company is not a party to any other material pending or threatened legal proceedings.

ITEM 5. OTHER INFORMATION

On August 11, 2011, the Company’s board of directors approved an amended and restated employment agreement (the “Agreement”) with the Company’s chief executive officer, Thomas Sandgaard. The Agreement provides for a three year term and provides for a severance payment equal to one year of Mr. Sandgaard’s base salary. The Agreement also provides Mr. Sandgaard with a base salary, bonus eligibility, a company car and certain other benefits available to our employees. The Agreement further subjects Mr. Sandgaard to a one year non-compete, confidentiality and other covenants.

ITEM 6. EXHIBITS

(a) Exhibits

Exhibit
Number			Description
3.1			Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on October 7, 2008)
3.2			Amended and Restated Bylaws (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed on October 7, 2008)
4.1			Form of Warrant (incorporated by reference to Exhibit 10.4 of the Company’s Quarterly Report on Form 10-QSB for the quarter ended June 30, 2006)
31.1	*		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
31.2	*		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
32.1	*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	*		The following financial statements, formatted in XBRL: (i) Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010, (ii) Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2011, (iii) Condensed Consolidated Statements of Stockholders’ Equity as of June 30, 2011, (iv) Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and June 30, 2011 and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text. The information in Exhibit 101 is ”furnished” and not “filed”, as provided in Rule 402 of Regulation S-T.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.